Methimazole and Carbimazole for Feline Hyperthyroidism: Pharmacology, Dosing, and Adverse Effect Management

Bottom line.

• Methimazole at 1.25–2.5 mg PO BID (cats <5 kg) or 2.5 mg PO BID (cats ≥5 kg) is the recommended starting dose for medical management of feline hyperthyroidism, with the 2016 AAFP guidelines endorsing titration to maintain serum TT4 between 1.0 and 2.5 µg/dL.^1,2
• In the landmark Peterson et al. 1988 cohort of 262 cats, clinical adverse effects occurred in 18.3% of cats (anorexia, vomiting, lethargy, self-induced facial excoriation, hepatopathy, bleeding diathesis), typically within the first month; serious hematologic reactions (agranulocytosis, thrombocytopenia) occurred in 3.8%.²
• Carbimazole is a prodrug rapidly converted to methimazole after oral absorption; the sustained-release formulation (Vidalta, 10 mg or 15 mg tablet SID) is widely used in Europe and may be better tolerated than standard methimazole, though head-to-head trial data in cats are limited.¹
• Transdermal methimazole in pluronic lecithin organogel (PLO gel) applied to the inner pinna is an alternative when oral dosing is not feasible; evidence supports efficacy but bioavailability is lower and more variable than oral administration.³
• This is a clinician-facing evidence summary. It is not a dosing protocol; confirm regimen, monitoring and contraindications against current product labeling and a veterinary formulary.

Drug facts

• Class: Thioamide antithyroid agent (thyroid peroxidase inhibitor).²
• Mechanism: Inhibits thyroid peroxidase, blocking organification of iodine and coupling of iodotyrosines, thereby reducing thyroid hormone synthesis. Does not block release of preformed hormone.¹
• Formulations: Methimazole tablets (2.5 mg, 5 mg); compounded oral liquid; transdermal PLO gel. Carbimazole: sustained-release tablet (Vidalta, 10 mg and 15 mg).^1,3
• Starting dose (methimazole): 1.25–2.5 mg PO BID; some practitioners use 2.5 mg SID initially to assess tolerability, escalating to BID.¹
• Monitoring: Recheck TT4, CBC, ALT, BUN, creatinine at 2–4 weeks, then 4 weeks after any dose adjustment; once stable, recheck every 3–6 months.¹
• Target TT4: 1.0–2.5 µg/dL (low-normal range).¹
• Carbimazole starting dose: 10 mg SID (sustained-release); titrate based on TT4 response.¹

Managing a hyperthyroid cat?

Get an instant cited answer — no signup needed for your first question. Voyage Clinical Desk brings species-specific evidence, monitoring plans, and dosing guidance to the case in front of you.

Try Voyage Clinical Desk

What the evidence shows

Efficacy: Peterson et al. 1988 foundational cohort

The earliest large evidence base for methimazole in cats comes from Peterson, Kintzer, and Hurvitz (1988), who evaluated 262 hyperthyroid cats over 3 years.² After 2–3 weeks of therapy at 10–15 mg/day, mean serum TT4 decreased significantly from 12.1 µg/dL to 2.1 µg/dL. In 81 cats given methimazole as sole long-term treatment, the final maintenance dose required to maintain euthyroidism ranged from 2.5 to 20 mg/day (mean 11.9 mg/day), reflecting considerable inter-individual variability. This study established the evidence base for methimazole as a cornerstone of medical management of feline hyperthyroidism.

Adverse effects: frequency and management

Clinical adverse effects occurred in 48 of 262 (18.3%) cats in Peterson et al. 1988, almost always within the first month of treatment.² These included:

• Gastrointestinal: Anorexia, vomiting, and lethargy — the most common adverse effects; often transient and can resolve with continued treatment or dose reduction.
• Self-induced facial excoriation: Pruritis leading to self-trauma around the face and neck, a distinctive and distressing side effect; onset typically within the first 4–8 weeks.
• Hepatopathy: Characterized by elevation in ALT and ALP, total bilirubin, and usually accompanied by lethargy, anorexia, and vomiting; prompts discontinuation.
• Hematologic abnormalities: Mild changes (eosinophilia, lymphocytosis, slight leukopenia) in 16.4%; serious reactions (agranulocytosis, thrombocytopenia) in 3.8%, requiring drug cessation — resolved within 1 week of stopping treatment.
• Immunologic: Antinuclear antibodies (ANA) developed in 21.8% of cats tested; a positive ANA alone is not sufficient reason to discontinue treatment if the cat is clinically well.

The 2016 AAFP Guidelines recommend that a CBC and serum chemistry panel be obtained before initiating methimazole and at 2–4 week intervals for the first 3 months due to the risk of hematologic toxicity.¹

Transdermal methimazole: evidence base

A prospective randomized crossover study by Sartor et al. (2004, JVIM) compared oral methimazole (2.5 mg BID) to transdermal methimazole in PLO gel (2.5 mg BID applied to the inner pinna) in 12 hyperthyroid cats.³ Oral methimazole normalized TT4 in 10/12 cats (83%) at 4 weeks; transdermal methimazole normalized TT4 in 7/12 (58%) cats. The transdermal route was associated with lower and more variable bioavailability but significantly reduced vomiting. The 2016 AAFP guidelines acknowledge transdermal PLO gel as an acceptable alternative for cats in which oral medication is not feasible, while noting that some cats may require higher doses to achieve adequate control.¹

Carbimazole: mechanism and formulations

Carbimazole is a prodrug that is de-esterified to methimazole in the gastrointestinal tract and liver following oral absorption; 5 mg of carbimazole is metabolically equivalent to approximately 3 mg of methimazole.¹ The sustained-release formulation (Vidalta) was developed specifically for cats to allow once-daily dosing. The 2016 AAFP guidelines note that carbimazole has the same mechanism of action, adverse effect profile, and monitoring requirements as methimazole and is widely used in Europe and Australia where it holds marketing authorization.¹

Pre-treatment trial of methimazole: the "reversibility test"

The 2016 AAFP guidelines recommend a 4-week methimazole trial before irreversible therapies (radioiodine or surgery) in cats with suspected concurrent chronic kidney disease (CKD), to assess renal function after restoration of euthyroidism.¹ Because hyperthyroidism-driven high cardiac output elevates GFR and can mask underlying azotemia, lowering thyroid hormone levels unmasks pre-existing CKD in 15–50% of cats. If azotemia develops during the methimazole trial, the clinician must weigh the risks and benefits of treatment modalities carefully.

Role within the treatment landscape

The 2016 AAFP guidelines delineate four treatment options for feline hyperthyroidism: radioiodine (I-131), thyroidectomy, medical management (methimazole/carbimazole), and dietary iodine restriction (Hill's y/d).¹ Medical management with methimazole or carbimazole is the most widely used approach in North America, largely due to the accessibility of oral medication compared to I-131 (which requires referral and radiation isolation) and surgery (anesthetic risk in geriatric cats). Unlike I-131 or surgery, antithyroid drugs do not cure hyperthyroidism; they control TT4 and must be continued lifelong.

How this fits clinical practice

Methimazole remains the default starting point for most newly diagnosed hyperthyroid cats, particularly where immediate assessment of renal response is warranted, owner compliance with daily medication is feasible, or radioiodine is not accessible. Starting at the lower end of the dose range (1.25–2.5 mg BID) and titrating based on 2–4 week TT4 rechecks minimizes adverse effect burden while achieving control. Facial excoriation and anorexia within the first month are the adverse effects most likely to drive owner concern; counseling owners at the outset about the probability and management of these effects improves compliance. For cats that cannot tolerate oral medication, transdermal PLO gel is a legitimate alternative, but efficacy should be confirmed with TT4 monitoring at 4 weeks given the lower bioavailability. Carbimazole (where available) offers the convenience of once-daily dosing.

Always confirm specific doses, monitoring schedules, and adverse effect management strategies against current product labeling, Plumb's Veterinary Drug Handbook, or equivalent formulary.

Voyage Clinical Desk

From clinical question to SOAP draft — cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk

References

1. Carney HC, Ward CR, Bailey SJ, Bruyette D, Dennis S, Ferguson D, Hinc A, Rucinsky AR. 2016. 2016 AAFP Guidelines for the Management of Feline Hyperthyroidism. J Feline Med Surg 18(5):400–416. https://pubmed.ncbi.nlm.nih.gov/27143042/
2. Peterson ME, Kintzer PP, Hurvitz AI. 1988. Methimazole treatment of 262 cats with hyperthyroidism. J Vet Intern Med 2(3):150–157. https://pubmed.ncbi.nlm.nih.gov/3265728/
3. Sartor LL, Trepanier LA, Kroll MM, Rodan I, Challoner L. 2004. Efficacy and safety of transdermal methimazole in the treatment of cats with hyperthyroidism. J Vet Intern Med 18(5):651–655. https://pmc.ncbi.nlm.nih.gov/articles/PMC1345727/

Changelog

• 2026-06-28: First published.